Full Breakdown
Definium Therapeutics' LSD-Based DT120 Meets Primary Endpoint in Phase 3 Depression Trial
6/22/2026, 10:46:32 PM
DT120 Achieves Primary Endpoint in Phase 3 Emerge Trial
Definium Therapeutics announced that its oral LSD tablet, DT120, met the primary efficacy endpoint in the Phase 3 Emerge study for major depressive disorder (MDD). The double-blind trial of 149 adults measured change on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6, showing an 8.1-point placebo-adjusted improvement (p < 0.0001). Benefits appeared early, with a 14.2-point advantage at week 1, and persisted through week 12.
Background: Psychedelic Therapies and Definium’s Evolution
Definium, renamed from MindMed in January 2026, focuses on psychedelic-based medicines. The company operates as psychedelics gain regulatory attention, including a 2025 executive order by President Donald Trump to advance such therapies and an FDA priority under former commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr.
Key Figures and Collaborators
CEO Rob Barrow presented the results, with investigator John Sonnenberg providing clinical interpretation. The findings are discussed alongside those of Compass Pathways, which recently reported a positive Phase 3 psilocybin trial for treatment-resistant depression.
Trial Design, Efficacy and Response Rates
Emerge tested a single 100-µg dose of DT120 ODT versus placebo. Response occurred in 35 % of DT120 patients versus 7 % on placebo (NNT?4). Remission rates were 24 % versus 3 % (NNT?5). Secondary measures, including Clinical Global Impressions, mirrored the primary MADRS outcome.
Safety and Tolerability
Adverse events were mild or moderate in 99 % of participants and limited to the dosing day. No serious events, suicidality signals, or higher discontinuation rates than placebo were observed.
Official Statements & Analyst Reactions
Stifel analysts said the data exceeded expectations with clear and highly robust efficacy in the MDD population. Jefferies called the efficacy profound compared with existing therapies. Barrow said DT120 could become a best-in-class option for mental health disorders and noted a compelling advantage over Spravato because of its durable response.
Criticism, Limitations, and Peer Reaction
Analysts noted the trial cannot directly compare DT120 with Johnson & Johnson’s Spravato because of differing study designs. Independent peer commentary remains limited, and broader validation through replication has not yet occurred.
Conflicting Reports & Gaps
All sources agree on the 8.1-point MADRS improvement at week 6; no contradictory efficacy data appear. Long-term safety beyond the 12-week follow-up remains unreported.
Verbatim Quotes
- “exceeded expectations with clear and highly robust efficacy in the MDD population.” — Stifel analysts
- “potential best-in-class treatment for mental health disorders” — Rob Barrow, CEO, Definium Therapeutics
- “meaningful and durable.” — John Sonnenberg, Investigator
- “0001), suggesting DT120 could offer faster relief than existing antidepressants, which typically take weeks to show meaningful benefit.” — Definium Therapeutics
What’s Next: Regulatory Path and Ongoing Studies
DT120 holds FDA Breakthrough Therapy Designation, positioning it for accelerated review. Definium plans a New Drug Application for MDD and continues the Ascend Phase 3 trial, which tests 100-µg and 50-µg doses. Additional programs explore DT120 in generalized anxiety disorder, post-traumatic stress disorder, and an MDMA formulation for autism spectrum disorder.
